

HEALIUS LIMITED
ACN 064 530 516
REGISTERED OFFICE:
LEVEL 6, 203 PACIFIC HIGHWAY
ST LEONARDS NSW 2065
TEL: +61 2 9432 9400

3 July 2019

ASX Limited
Market Announcements Office
ASX Limited
20 Bridge Street
Sydney NSW 2000

Dear Sir/Madam

APPENDIX 3Y – MALCOLM PARMENTER

Enclosed is an Appendix 3Y in respect of the issue of Performance Rights to Malcolm Parmenter, Managing Director and CEO of Healius Limited (**Healius**).

It has become apparent during the preparation of an Appendix 3Y for Dr Parmenter, dealing with the recent issue of ordinary shares (of which Dr Parmenter received a portion), that there has been an oversight in relation to notification of an issue of Performance Rights to Dr Parmenter which occurred on 29 January 2019.

Although a Listing Rule 3.10.3 letter was lodged with ASX on 29 January 2019, covering the issue of Performance Rights to Long-term Incentive Plan participants as a whole (including Dr Parmenter), no Appendix 3Y was lodged at the time in respect of Dr Parmenter.

Please note that the Appendix 3B dated 2 July 2019 is not affected in any respect and no other Directors or other Key Management Personnel of Healius are affected.

Steps have been taken to ensure that the same internal procedures applied to issues of quoted securities are also applied in full to unquoted securities, so that the chances of such errors being repeated are minimised.

Yours sincerely,

A handwritten signature in cursive script, appearing to read 'Charles Tilley'.

Charles Tilley
Company Secretary

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HEALIUS LIMITED
ABN	24 064 530 516

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Malcolm Parmenter
Date of last notice	15 October 2018

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct						
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	As shown in relation to ordinary shares Not applicable in relation to Service Rights Not applicable in relation to Performance Rights						
Date of change	29 January 2019						
No. of securities held prior to change	<table><tr><td>59,597 Ordinary shares</td><td>Malcolm W Parmenter Pty Ltd atf Malcolm W Parmenter Superannuation Fund</td></tr><tr><td>51,998 Service Rights</td><td>Malcolm Parmenter</td></tr><tr><td>475,180 Performance Rights</td><td>Malcolm Parmenter</td></tr></table>	59,597 Ordinary shares	Malcolm W Parmenter Pty Ltd atf Malcolm W Parmenter Superannuation Fund	51,998 Service Rights	Malcolm Parmenter	475,180 Performance Rights	Malcolm Parmenter
59,597 Ordinary shares	Malcolm W Parmenter Pty Ltd atf Malcolm W Parmenter Superannuation Fund						
51,998 Service Rights	Malcolm Parmenter						
475,180 Performance Rights	Malcolm Parmenter						
Class	Performance Rights						
Number acquired	804,980						

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number disposed	N/A	
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	N/A	
No. of securities held after change	59,597 Ordinary shares	Malcolm W Parmenter Pty Ltd atf Malcolm W Parmenter Superannuation Fund
	51,998 Service Rights	Malcolm Parmenter
	1,280,160 Performance Rights	Malcolm Parmenter
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Performance Rights relating to FY2019 under the Long Term Incentive Plan (granted by Board on 25 January 2019 - refer LR3.10.3 letter dated 29 January 2019), to Managing Director & Chief Executive Officer; pursuant to shareholder approval at 2018 Annual General Meeting. Performance testing period is FY2019-FY2021 inclusive.	

Part 2 – Change of director's interests in contracts Not applicable

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

Charles Tilley
Company Secretary
Date: 3 July 2019

⁺ See chapter 19 for defined terms.